Mutations in PATCHED (PTC), the human homolog of the Drosophila patched gene, have been identified in most exons of the gene in patients with the basal cell nevus syndrome and in sporadic basal cell carcinomas. We have screened the 23 PTC exons for mutations using single strand conformation polymorphism analysis of DNA from 86 basal cell nevus syndrome probands, 26 sporadic basal cell carcinomas, and seven basal cell nevus B asal cell carcinomas (BCC) are the commonest human cancer, with an estimated 750,000 cases per year in the U.S.A. alone (Miller and Weinstock, 1994) . The great majority of these occur on sun-exposed skin, and their steadily rising incidence is commonly attributed to ultraviolet mutagenesis accompanying increased recreational sun exposure. BCC also occur in the context of the BCNS (nevoid basal cell carcinoma syndrome, Gorlin Syndrome, MIM #109400), a rare autosomal dominant disease in which patients have both developmental (e.g., skeletal) abnormalities and postnatal tumors (e.g., BCC, which occur in greater numbers and at an earlier age than in sporadic cases, and medulloblastomas) (Gorlin, 1987) . Positional cloning efforts in many laboratories extending over a decade, culminated in 1996 in the identification of heritable mutations in PTC in patients with the BCNS and somatic mutations in PTC in sporadic BCC (Johnson et al, 1996; Hahn et al, 1996) , and subsequently in the identification of PTC gene mutations in sporadic medulloblastomas and other cancers (Raffel et al, 1997; Xie et al, 1997; Wolter et al, 1997) .
syndrome-associated basal cell carcinomas. This screen identified mutations located in eight exons in 13 of the basal cell nevus syndrome patients and in three of the tumors. The most common mutations were frameshifts resulting in premature chain termination. These results provide further evidence for the crucial role of PTC as a tumor suppressor in human keratinocytes. Keyword: Hedgehog. J Invest Dermatol 110:885-888, 1998 Marigo et al, 1996) or following mutational inactivation of Ptc. Smo signaling activates transcription of Hh targets including PTC, and there is consistent upregulation of PTC transcription in BCC (Gailani et al, 1996b; Unden et al, 1997; Kallassy et al, 1997) . BCC-like epidermal proliferation and BCNS-like skeletal abnormalities are produced by overexpression of Shh in murine and human epidermal keratinocytes, and identical (presumably activating) SHH somatic mutations have been identified in a sporadic basal cell carcinoma, a medulloblastoma, and a breast carcinoma Fan et al, 1997) .
Further, mutations in SMO also can be found in BCC (Xie et al, 1998) . Thus, activation of transcription of Hh targets can be effected by mutations in any of the three components of the signaling pathway that interact at the cell membrane -activating mutations in the protooncogenes SHH and SMO or inactivating mutations in the tumor suppressor gene PTC.
MATERIALS AND METHODS

Subjects
One affected person from each of 86 unrelated BCNS kindreds was studied. All studied patients had multiple BCC with onset in the second decade of life in addition to at least one of the following: multiple keratocysts of the jaw, palmar pits, or skeletal abnormalities. No patients meeting the above criteria were excluded from the screen.
DNA isolation, amplification, and single strand conformation polymorphism (SSCP) analysis DNA was extracted from blood samples using standard phenol-chloroform extraction techniques. Paraffin-embedded BCC DNA was isolated as reported previously (Bonifas et al, 1994) . All studied BCC occurred on sun-exposed sites. The following polymorphic microsatellite repeat loci for chromosome 9q were used to determine allelic deletions: D9S152, D9S176, D9S180, D9S196, D9S197, D9S12, D9S119, D9S127, D9S280, D9S287 (Bonifas et al, 1994; Xie et al, 1997) .
SSCP analysis was performed using intronic primers designed to flank each of the 23 exons of PTC (Xie et al, 1997) . Forward primers were end-labeled with γ P 32 , and exons were amplified by PCR. PCR was carried out using 100 ng of genomic DNA with amplification conditions as follows: denaturation for 1 min at 95°C, annealing at 55°C for 1Ј30Љ, extension at 72°C for 1Ј30Љ for 35 cycles. Amplification products were diluted 1:7 in stop solution, heated to 90°C for 5 min, and then chilled on ice prior to loading 3.5 µl on a MDE gel (BMC bioproducts) at room temperature or 4°C and run at 6 W for 10-12 h. After electrophoresis, the gels were transferred to Whatman chromotography paper and dried for 1 h at 94°C. Autoradiography with Kodak XAR film at room temperature allowed detection of PCR products after a 24 h exposure (Chen et al, 1995) .
DNA cloning and sequencing
Exons with detectable SSCP abnormalities were sequenced. PCR was performed under the same conditions described for SSCP. Direct sequencing was performed on samples using Sequenase PCR Product Sequencing Kit (Amersham Life Science). Further mutation detection was pursued in a subset of samples by cloning purified PCR product into plasmid vector pCR2.1 (Invitrogen) and sequencing cloned material either by the Sequenase Sequencing kit or by automated sequencing using the ABI Prism sequencer.
RESULTS
Of 26 sporadic BCC screened, 11 showed loss of heterozygosity at one or more of the polymorphic markers examined in the PTC gene region. All markers were at least 80% informative. Of these 11, three tumors were found to have PTC gene mutations, each in a different exon of the gene. One of these is predicted to result in an amino acid substitution, one in a premature stop codon, and one in a frameshift. The latter two of these identified BCC mutations cause premature chain termination. These three mutations are not those considered to be characteristic of UV-induced changes. Two of the mutations occurred in exons encoding Ptc protein cytosolic loop regions and one occurred in an exon encoding a transmembrane domain. We found no SSCP abnormalities in DNA from the 15 tumors that lacked loss of heterozygosity. Of the eight BCNS-associated BCC, two showed loss of heterozygosity and one of these had identical mutations identified in constitutional and tumor DNA. The results are summarized in Table I . We identified 13 PTC mutations among the DNA samples screened from the 86 probands. These mutations were found in nine different exons. Nine of the 13 resulted in frameshifts (Fig 1) , one resulted in an amino acid substitution, one in a premature stop codon, one in an amino acid insertion, and one in disruption of a splicing site. The results are summarized in Table I .
DISCUSSION
PTC gene mutations were identified in 13 of 86 BCNS probands, in three of 26 sporadic BCC, and in one of eight BCNS-associated BCC. Each of the BCC in which a mutation was identified had sustained deletion of the second allele. Our data are consistent with the conclusion that PTC acts as a classic tumor suppressor gene, requiring ''two hits'' for tumorigenesis (Knudson, 1971) in at least some BCC. Sporadic BCC require mutations of both alleles of PTC by postnatal insults such as UV or X-ray irradiation, chemical carcinogenesis, or random genetic alteration. In contrast, BCNS patients have greater susceptibility to tumorigenesis: they inherit a germline mutation of one allele of PTC and require only one postnatal genetic ''hit'' to inactivate the remaining wild-type allele.
The three PTC mutations in sporadic BCC from UV-exposed sites reported herein are not characteristic of UV-induced mutagenesis, although one (a deletion of base pair 1887) occurs at a dipyrimidine site. In contrast, 11 of 24 previously reported mutations in PTC in sporadic BCC have been of the UV signature type (Gailani et al, 1996b; Unden et al, 1996; Hahn et al, 1996; Johnson et al, 1996; Wolter et al, 1997) . UVB-type signature mutations including C→T and CC→TT base substitutions comprise the majority of p53 gene mutations found in Caucasians in both BCC (65%) (Rady et al, 1992; Moles et al, 1993; Ziegler et al, 1993; van der Riet et al, 1994; Gailani et al, 1996a) and squamous cell carcinomas (SCC) (67%) (Brash et al, 1991; Pierceall et al, 1991; Moles et al, 1993) . The lower incidence of UVB signature mutations in PTC (11 of 27, 41%) suggests that mutagenic events other than UV irradiation may also cause Ptc inactivation and trigger tumorigenesis. Furthermore, this relatively low fraction of BCC cells that have UVB induced mutations is consistent with epidemiologic studies that have found poor correlation between UVB dose and incidence of BCC, unlike the better correlation between UVB dose and the incidence of SCC (Strickland et al, 1989; Vitasa et al, 1990) .
Thirteen of the 16 mutations identified are expected to result in protein truncation, with the most proximal site being the first extracellular loop. Approximately 75% of previously reported constitutional mutations in BCNS patients and somatic mutations in BCC (whether in BCNS patients or in nonaffected persons) are predicted to cause premature protein truncation (Hahn et al, 1996; Johnson et al, 1996; Gailani et al, 1996b; Unden et al, 1996; Chidambaram et al, 1996; Wicking et al, 1997; Wolter et al, 1997; Lench et al, 1997) . In addition, mutations in exons 6 and 8 appear to be a common site of PTC mutation (eight of 52 reported mutations in BCNS probands occur in these exons). The identification of two mutations in exons encoding the fourth cytosolic loop and the eleventh transmembrane domains in this study provides further evidence for the importance of these terminally located structures to Ptc protein tumor suppressor function. The mechanism by which these and other mutations alter the function of the human Ptc protein remains to be elucidated, but they are consistent with the idea that loss of Ptc protein function results in BCC tumorigenesis.
In Drosophila, Ptc functions as a critical component of the HHSP. Hedgehog, a diffusible protein, binds to and inhibits Ptc. In the absence of hedgehog inhibition, Ptc acts to inhibit Smo, an adjacent transmembrane protein. In Drosophila, activated Smo signaling activates Cubitus Interruptus, which encodes a transcription factor that is homologous to the human Gli family proteins (Von Ohlen et al, 1997) . Cubitus Interruptus activates transcription of wingless, ptc, and decapentaplegic and represses transcription of hedgehog (Aza-Blanc et al, 1997; Von Ohlen et al, 1997) .
The presence of a homologous HHSP that can result in tumorgenesis in mammals is suggested by the recent report that overexpression of wild-type Shh or mutant Smo in the epidermis of transgenic mice produces BCC-like proliferations in the skin Xie et al, 1998) . In addition, in vitro transformation of cell lines with an expression vector containing a mutant SMO gene in cooperation with an EIA-expressing construct resulted in an altered cell phenotype with loss of contact inhibition and formation of foci of transformation (Xie et al, 1998) . Finally, in situ studies indicate that there is heightened transcription of PTC and GLI mRNA in BCC, whereas normal epidermis has no detectable PTC mRNA expression (Gailani et al, 1996b; Unden et al, 1997; Dahmane et al, 1997) .
Although no kindred with mapping of the BCNS gene to any site other than chromosome 9q has been reported, we like others have identified PTC gene mutations in a rather low percentage of BCNS families. Possible explanations for this discrepancy may include insensitivity of SSCP, and indeed Hahn et al (1996) and Wicking et al (1997) found PTC gene mutations by sequencing samples without detectable SSCP abnormalities. In addition, SSCP temperature conditions were varied (22°C and 4°C) for only two exons due to limitations in the quantity of patient DNA, and this did in fact yield an additional aberrant band (due to a T2132 del) that had not been found at room temperature. Although only these two exons were additionally screened at this low temperature, it could be extrapolated that had there been sufficient patient DNA, further mutations might have been identified. Alternate explanations for our low mutation identification rate include possible promoter or enhancer region abnormalities, abnormal methylation, or the presence of another tumor suppressor gene in the same chromosomal region.
Future studies will delineate the effect of mutant Ptc, Shh, and Smo proteins on downstream HHSP components, including Gli, Wnt, and TGF-β, the mechanism by which HHSP target gene transcription triggers tumorigenesis, and therapeutic modes of suppressing pathway activation.
